series-a
Stage
1
Investors
About
Akero Therapeutics develops novel therapies to treat nonalcoholic steatohepatitis (NASH) and other cardiometabolic diseases.
Explore Akero Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.